World Autism Awareness Day is observed annually on April 2, a day designated by the United Nations to encourage member nations to take steps to raise awareness of autism.
Autism, or autism spectrum disorder, indicates a wide range of conditions, including challenges with social skills, repetitive behaviors, speech and non-verbal communication, according to Autism Speaks. Signs related to this disorder begin to manifest mostly between 2 and 3 years of age, and in some cases as early as 18 months. Male children are more prone to autism than females.
One in 68 children in the U.S. shows symptoms of autism, according to Autism Speaks, which cited data from the Centers for Disease Control and Prevention.
Globally, ASD pccurs in one out of every 160 people, according to the World Health Organization’s estimates.
Autism is mostly accompanied by some medical and mental health issues such as gastrointestinal disorders, seizures, sleep disturbances, attention deficit hyperactivity disorder, or ADHD, anxiety and phobias.
No FDA-approved drug exists to treat the core symptoms of autism spectrum disorder.
Breakthrough therapy designation is accorded to drug candidates that have the potential to treat serious or life-threatening conditions and expedites the FDA’s review process.
The drug candidate is a vasopressin 1a (V1a) receptor antagonist for individuals with ASD. The candidate is being tested in a Phase 2 trial.
The logic behind the functioning of balovaptan is as follows: the blocking of the activity of vasopressin, a neuropeptide believed to be an influencer of social bonding, at one receptor will help improve social functioning and avoid the side effects of increased vasopressin across the board, which is believed to lead to increased aggression, according to Fierce Pharma.
Among the other research on this front, scientists at the Stanford University are testing a nasal spray of vasopressin in people with autism — an approach different from Roche’s. With a preliminary study showing improvement, the treatment option is now being tested in a 100-patient trial that’s expected to be complete by the end of 2022.
Studies have also found that oxytocin, another neuropeptide, was effective in treating ASD, especially in patients with autism and very low oxytocin levels.
Companies that have researched Fragile X syndrome, a common cause of autism, have not met with much success.
Seaside Therapeutics also discontinued the mid-stage trial of its lead ASD drug candidate STX209 in 2013. The company, however, has three product candidates — namely STX209, STX107 and STX110 — in various stages of human testing.